Meta AnalysisID 181
南非醉茄（Withania somnifera）在应激与焦虑中的抗焦虑和适应原活性——系统评价
CRD42022351907
“Ashwagandha (Withania somnifera) have anxiolytic and adaptogenic activity in individuals with anxiety, stress and post-traumatic stress disorder?” P - Population: Humans of any age or gender, with stress, anxiety and po
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Herb: 1Meta-analysis: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final meta_analysis record.
- Meta Analysis Id
- 181
- Evidence Id
- 8739
- Core Evidence Id
- 8739
- Source Meta Analysis Id
- 166
- Herb2 Meta Analysis Id
- HBMA000166
- Crd Id
- CRD42022351907
- Title
- Anxiolytic and adaptogenic activity of Ashwagandha (Withania somnifera) in cases of stress and anxiety - A Systematic Review
- Review Question
- “Ashwagandha (Withania somnifera) have anxiolytic and adaptogenic activity in individuals with anxiety, stress and post-traumatic stress disorder?” P - Population: Humans of any age or gender, with stress, anxiety and post-traumatic stress disorder. I - Intervention: Ashwagandha (Withania somnifera) in any form and preparation, dose and duration, in monotherapy. C - Control/Comparison: Placebo, conventional therapy or no intervention/treatment.. O - Outcome: Anxiolytic and adaptogenic activity in cases of anxiety, stress, and post-traumatic stress disorder, with consequent improvement in quality of life and improvement in cognitive function.
- Study Type Included
- Randomized clinical trials in humans of any age or gender, evaluated the use of Ashwagandha (Withania somnifera) in any form and preparation, dose and duration, in monotherapy. Primary outcome: anxiety, stress, and post-traumatic stress disorder. Secondary outcomes: quality of life, cognitive improvement, intervention safety, and possible adverse events. No language or publication period limitations were established for selecting primary studies. Exclusion criteria: (1) animal or in vitro studies; (2) studies that do not include any results on stress or anxiety; (3) studies that are not randomized clinical trials, such as reviews, letters, conference abstracts, personal opinions, book chapters, retrospective, descriptive, and observational studies, study protocols, dissertations, theses, institutional manuals, and case or series reports ; (4) studies that do not use Ashwagandha (Withania somnifera) in monotherapy; (5) studies unrelated to the topic; (6) duplicate studies.
- Condition Being Studied
- Mental disorders are psychological manifestations associated with some functional impairment resulting from biological, social, psychological, genetic, physical or chemical dysfunctions, producing losses in the person's overall performance in the personal, social, occupational and family spheres. The COVID-19 pandemic and the recommended control measures have had adverse impacts on mental health, with negative effects on daily life and the quality of people's health. Quarantined individuals reported a higher prevalence of psychological symptoms such as emotional distress, depression, stress, irritability, anxiety, and post-traumatic stress symptoms. Anxiety disorders include disorders that share characteristics of excessive fear and anxiety and related behavioral disorders. Considered a natural reaction of the human being when placed in unusual and unpleasant situations, anxiety becomes pathological when its symptoms are aggravated, making self-control impossible. Physical symptoms may be experienced, including restlessness or a feeling of “nerves on the edge”; fatigability; Difficulty concentrating; irritability; muscle tension; and sleep disorders. Post-traumatic stress disorder is a type of anxiety disorder that can develop in people who have been exposed to a traumatic, stressful and/or violent event that threatens their own life or the lives of others.
- Participant
- Humans of any age or gender, with stress, anxiety and/or post-traumatic stress disorder.
- Animal
- Human Disease Modelled
- Intervention
- Ashwagandha (Withania somnifera) in any form and preparation, dose and duration, in monotherapy.
- Comparator Control
- Placebo, conventional therapy or no intervention/treatment.
- Main Outcome
- Anxiolytic and adaptogenic activity on anxiety, stress, and post-traumatic stress disorder.
- Outcome Measure
- Additional Outcome
- Quality of life, cognitive improvement, intervention safety, and possible adverse events.
- Study Method
- Intervention, Systematic review
- Keyword
- Anti-Anxiety Agents; Anxiety; Ashwagandha; Humans; Plant Extracts; Withania
- Contact
- Francine Campos [email protected]
- Organisational Affiliation
- Secretaria Municipal de Saude de Sao Paulo
- Funding Source
- No funding/sponsors
- Other Selection Criteria
- Final Publication
- Same Topic Review
- Published Protocol
- Review Type
- Language
- English, Portuguese-Brazil
- Country
- Brazil
- Review Stage
- Review Completed not published
- First Submission Date
- 2022-08-06
- Registration Date
- 2022-08-17
- Anticipated Start Date
- 2022-04-04
- Anticipated Completion Date
- 2023-01-10
- Title Cn
- 南非醉茄（Withania somnifera）在应激与焦虑中的抗焦虑和适应原活性——系统评价
- Title En
- Anxiolytic and adaptogenic activity of Ashwagandha (Withania somnifera) in cases of stress and anxiety - A Systematic Review
- Bilingual Status
- complete